Aurobindo Pharma's CuraTeQ Gets Nod For Cancer Drug From UK Regulator

Aurobindo Pharma is one of the key players in the large Indian pharma industry. In a major development for the company, the pharma company has announced the approval of a crucial cancer drug from the United Kingdom regulator.

Aurobindo Bags Approval For Cancer Drug

Aurobindo Pharma's subsidiary, CuraTeQ Biologics got the green signal for the oncology biosimilar Bevqolva. CuraTeQ Biologics obtained marketing authorisation from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA).

The company announced this through an exchange filing on Saturday, December 21.

The Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins.

Cancer Treatment In Focus

Bevacizumab is used to treat a variety of cancers. The list of ailments that be treated with this drug include cervical cancer, epithelial ovarian, fallopian tube, and primary peritoneal cancer, metastatic colorectal cancer, advanced and/or metastatic renal cell carcinoma, recurrent or metastatic non-squamous non-small cell lung cancer, and cervical cancer.

Aurobindo Shares

When we take a look at Aurobindo Pharma's recent performance at Dalal Street, although the Hyderabad-based company's shares ended the week with gains in the 5-day trade period. The said gains were however depleted or diminished by the stock's performance on Friday, December 20.

The stocks ended the week, with an increase of 1.11 per cent or Rs 13.60.

When we take a specific look at the share performance on Friday, the stocks opened at Rs 1,254.80, which is only marginally higher than the previous day's closing of Rs 1,254.70.

After hitting a high of Rs 1,275.30 per share, the shares declined further by 1.09 per cent or Rs 13.70. This took the overall value of Rs 1,241.00 per share.

The company stocks' 52-week-high stood at Rs 1,592.00 per share, meanwhile the stock's 52-week-low stood at Rs 958.50 per share.